PMID-36056913 – Thymalfasin Pilot RCT for COVID-19
Shehadeh F et al. "A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection," Journal of Infectious Diseases, 2023;227(2):226-235. doi:10.1093/infdis/jiac362
Quick Reference
| Property | Value |
|---|---|
| PMID | 36056913 |
| DOI | 10.1093/infdis/jiac362 |
| Year | 2023 |
| Journal | Journal of Infectious Diseases |
| Study Type | RCT |
| Evidence Level | II |
| Sample | n=49 hospitalized COVID-19 patients with hypoxemia and lymphocytopenia |
| Peptide(s) Studied | Thymosin Alpha-1 |
Key Findings
- Thymosin alpha-1 significantly accelerated CD4+ T-cell recovery by day 5 vs. standard care
- Provides mechanistic evidence for immunomodulatory benefit in acute viral lymphocytopenia
- Small sample size limits conclusions on clinical outcomes (mortality, ICU admission)
Study Design
Prospective, open-label, randomized pilot trial. 49 hospitalized COVID-19 patients with hypoxemia and lymphocytopenia randomized to thymalfasin + standard care vs. standard care alone. Primary: CD4+ T-cell count trajectory.
Limitations
- Small sample (n=49); pilot study not powered for clinical outcomes
- Open-label design; no blinding
- Single-center; limited generalizability
- COVID-19 treatment landscape has changed substantially
Clinical Relevance
Provides mechanistic evidence for Tα1's immunomodulatory mechanism (CD4+ T-cell restoration) in human viral infection. Published in a high-impact infectious disease journal. Supports the rationale for Tα1 in lymphocytopenia-associated conditions beyond COVID-19.
Related
#research #RCT #evidence-level-II